Grifols rises after Q1 beat

Grifols SA

13/05/2025 08:27

** Shares of Grifols GRLS.MC rise 4% after the Spanish drugmaker reported Q1 results ahead of expectations, helped by plasma-derived medicine business

** "In comparison to latest consensus, Q1 revenues were 1% ahead, reported EBITDA was 5% ahead and adj. EBITDA was 7% ahead," J.P.Morgan says

** Grifols' net revenue rose 7.4% to 1.79 billion euros in the first quarter, driven by strong performance within plasma-derived medicine business

** Despite the beat, the group did not upgrade its guidance citing volatility, tariffs and currency moves

** Grifols shares top Madrid's IBEX 35 .IBEX index

 (Reporting by Joao Manuel Mauricio)

 ((JoaoManuel.VicenteMauricio@thomsonreuters.com))